ACAD - Trial Setback For Acadia Pharmaceuticals' Late-Stage Schizophrenia Trial: Details | Benzinga
Monday, Acadia Pharmaceuticals Inc (NASDAQ:ACAD) released top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for negative symptoms of schizophrenia.
Pimavanserin did not demonstrate a statistically significant improvement over placebo on the study’s primary endpoint, the change from baseline to week 26 on the Negative Symptom Assessment-16 (NSA-16) total score (-11.8 vs. -11.1; p=0.4825; effect size=0.07).
“We will continue to analyze these data with our scientific advisors, but we do not intend to conduct any further clinical trials with pimavanserin. We want to thank the patients, their families, and the investigators for ...